Icon

Istodax - (10 mg/vial; Powder, Intravenous)

Romidepsin Celgene
10 mg/vial; Powder, Intravenous
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
None
Less Than 5
None
second-line treatment for cutaneous T-cell lymphoma, or CTCL.
Yes
********* ** *** ***** ** **** **** ** **** ******* '***, '*** **** ******** ** *** **, **** *** *** ************ *********. ******* *** ********** ** ******* **** ********* ***** *** ***** ** ********* *** *** *****. ** ****** ********* ** ****** ********* ****** ****. ******* **** ***** **** ** **** **** ******* *** *** ************ *********. ** ****** **** **** **** ****** ** *** ****. * ******* ********** *** ** ******** **** **** ** ****, ***** **** ***** ****** *** **** ***** *********.
Istodax Patent 1 Patent 2
********** ******* *******
**** ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
********** *** \ ** *** **, **** ******* **** ******** ** *** **, **** ** **
**** ** \ ** *** **, **** ******* **** ******** ** *** **, **** ** **
  1. *** **, **** : ********* ******** ******* ***** *** **** ** **** ******* '***, '*** **** ******** ** *** **, ****.
  2. *** **, **** : ******* ***** * **** ******* ********* ** ******** ***** ** ********.
  3. *** **, **** : ********** *** ******* **** ********* ***** *** ***** ** ********* *** *** *****.
  4. *** **, **** : ******* ***** * **** ******* **** ** ******** ***** ** ******** ** **** ***** **** ** **** ******* '***, '*** **** ******** ** *** **, ****.
  5. *** **, **** : ********** *** ******* **** ****, ***** *** ***** ** ********* *** *** *****.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.